Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PSMA3 antisense RNA 1 (PSMA3-AS1) is a long non-coding RNA (lncRNA) that is transcribed antisense to the PSMA3 gene. It is not a protein but a regulatory RNA molecule. PSMA3-AS1 is involved in the regulation of various cellular functions such as proliferation, migration, invasion, and apoptosis, especially in the context of tumor biology. It acts as a competing endogenous RNA (ceRNA), sequestering specific microRNAs (such as miR-329-3p, miR-302a-3p, and miR-154-5p), thereby modulating the expression of downstream target genes like ALDOA, RAB22A, and KPNA4. Overexpression of PSMA3-AS1 has been documented in several types of cancer, including glioma, gastric cancer, pancreatic ductal adenocarcinoma, ovarian, lung, and colorectal cancers, where it often functions as a pro-oncogenic factor promoting tumor growth and metastasis. PSMA3-AS1 may serve as a biomarker for disease progression and a potential therapeutic target in oncology research[1][2][3].
Sponging microRNAs (e.g., miR-329-3p, miR-302a-3p, miR-154-5p); Modulating target gene expression (e.g., ALDOA, RAB22A, KPNA4)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PSMA3 antisense RNA 1 (PSMA3-AS1).